Dorothy Keefe

Adelaide Medical School

Faculty of Health and Medical Sciences

Professor Keefe is the CEO of Cancer Australia, and an honorary Clinical Professor in the School of Medicine at the University of Adelaide. She has had a long career as a Medical Oncologist, and Professor of Cancer Medicine.Her areas of expertise include gastrointestinal toxicity of cancer treatment, Supportive Care in Cancer more broadly, Medical Leadership and Health Reform, and she has published extensively in the Supportive Care literature. She has a long-standing commitment to the Multinational Association of Supportive Care in Cancer (MASCC), and is a past-president. All her work is focused on improving outcomes for patients .

My Research
Career
Publications
Grants and Funding
Teaching
Supervision
Professional Activities
Contact

Professor Keefe is the Interim Director of the SA Cancer Service, Professor of Cancer Medicine at the University of Adelaide, and a Senior Medical Oncologist at Royal Adelaide Hospital. She is a Past-President of the Multinational Association of Supportive Care in Cancer (MASCC).

Dorothy Keefe graduated in Medicine from the University of London in 1986, migrated to Australia and became a Fellow of the Royal Australasian College of Physicians (FRACP) in 1996. She received her Doctorate of Medicine from the University of Adelaide in 1999, for a thesis entitled ‘The effect of cytotoxic chemotherapy on the mucosa of the small intestine’.

Professor Keefe’s research interest is in toxicity of cancer treatment, particularly mucositis and how it links to other toxicities. Her laboratory work investigates chemotherapy and radiotherapy-induced whole gut damage, and the efficacy of new agents in prevention and treatment. She has authored over 100 peer-reviewed publications in this area.

In the 2013 Queen’s Birthday Honours Professor Keefe received the Public Service Medal for “outstanding service in the areas of Public Health, Medical Research and Oncology”. And in 2014 she received the MASCC Distinguished Service Award for “longstanding, devoted and exemplary service to MASCC”.

She has recently completed a Master’s of Science (MSc) in Medical Leadership at Birbeck College, University of London and her thesis was titled “Using Clinical Leadership to Drive Success in Making the ‘Case for Change’ for Healthcare Reform: A Case Study from the South Australian Transforming Health Program.

Appointments

Date	Position	Institution name
2019 - 2019	Professor of Cancer Medicine	University of Adelaide
2014 - 2017	Clinical Ambassador	SA Health
2011 - 2015	Service Director	SA Cancer Service SA Health
2010 - 2011	Regional Clinical Director	Adelaide Health Service Cancer Services
2009 - 2013	Chair	South Australian Cancer Clinical Network, SA Health
2007 - 2010	Clinical Director	Royal Adelaide Hospital
2007 - 2009	Chair MBBS Curriculum Committee (Operations)	University of Adelaide
2007 - 2009	Deputy Chair	South Australian Cancer Clinical Network
2006 - 2008	Chair MBBS Curriculum Committee	University of Adelaide
2006 - 2007	Interim Clinical Director	Royal Adelaide Hospital
2005 - 2007	Associate Professor in Oncological Medicine	The University of Adelaide
2001 - ongoing	Senior Consultant Medical Oncologist	Royal Adelaide Hospital
2000 - 2004	Clinical Senior Lecturer	University of Adelaide
1999 - 2002	Consultant Medical Oncologist (Access appointment)	Queen Elizabeth Hospital
1999 - 2001	Associate Specialist	Queen Elizabeth Hospital
1996 - 2000	Consultant Medical Oncologist	Royal Adelaide Hospital
1996 - 1999	Clinical Lecturer	University of Adelaide
1996 - 1997	Anti-Cancer Foundation Research Associate	Queen Elizabeth Hospital
1995 - 1998	Gastroenterology Research Fellow	Queen Elizabeth Hospital
1992 - 1994	Medical Oncology/Haematology Registrar	Queen Elizabeth Hospital
1989 - 1992	Basic Physician Trainee	Queen Elizabeth Hospital
1988 - 1988	Senior House Officer	Royal Cornwall Hospital
1987 - 1988	Medical Officer/Watch Officer	Britain Australia Bicentennial Schooner Trust
1986 - 1987	Medical and Surgical House Officer	Royal Cornwall Hospital

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
2014	Award	MASCC Distinguished Service Award	Multinational Association of Supportive Care in Cancer	-	-
2013	Honour	Public Service Medal	Queen's Birthday Honour	Australia	-
2009	Fellowship	Woman of Achievement Award	Royal College of Physicians (London)	United Kingdom	-
1998	Award	Clinical Research Prize	Queen Elizabeth Hospital Research Day	Australia	-
1993	Award	Clinical Research Prize	Queen Elizabeth Hospital Research Day	Australia	-
1993	Award	Best Physician Trainee	Queen Elizabeth Hospital	Australia	-

Journals

Year	Citation
2024	Abdalla-Aslan, R., Bonomo, P., Keefe, D., Blijlevens, N., Cao, K., Cheung, Y. T., . . . Nagano, C. (2024). Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. eClinicalMedicine, 73, 102675-1-102675-12. DOI
2023	Anderson, K., Gall, A., Butler, T., Ngampromwongse, K., Hector, D., Turnbull, S., . . . Garvey, G. (2023). Development of Key Principles and Best Practices for Co-Design in Health with First Nations Australians. International Journal of Environmental Research and Public Health, 20(1), 147. DOI Scopus11 Europe PMC5
2023	Chaji, D., Boltong, A., Der Vartanian, C., Lambert, A., Toms, C., Milch, V., . . . Keefe, D. (2023). Setting the policy agenda for cancer control reform: Australia's first national cancer control plan. Medical Journal of Australia, 219(10), 451-454. DOI Scopus2
2023	Korver, S. K., Bowen, J. M., Gibson, R. J., Ball, I. A., Secombe, K. R., Wain, T. J., . . . Coller, J. K. (2023). Advanced statistics identifcation of participant and treatment predictors associated with severe adverse efects induced by fuoropyrimidine‑based chemotherapy. Cancer Chemother Pharmacol, 91(6), 507-521. DOI Scopus1 Europe PMC1
2023	Chan, R. J., Milch, V. E., Crawford-Williams, F., Agbejule, O. A., Joseph, R., Johal, J., . . . Hart, N. H. (2023). Patient navigation across the cancer care continuum: An overview of systematic reviews and emerging literature. CA: A Cancer Journal for Clinicians, 73(6), 565-589. DOI Scopus59 WoS10 Europe PMC28
2022	Body, A., Milch, V., McSorley, L., Lal, L., Ahern, E., Ryan, R., . . . Segelov, E. (2022). Rapid Protocol Development, Study Startup and Enrolment of a Prospective Study of COVID-19 Vaccination for Patients with Cancer: A Collaborative Approach. Vaccines, 10(12), 2003. DOI
2022	Milch, V., Nelson, A. E., Austen, M., Hector, D., Turnbull, S., Sathiaraj, R., . . . Keefe, D. (2022). Conceptual Framework for Cancer Care During a Pandemic Incorporating Evidence From the COVID-19 Pandemic. JCO global oncology, 8(8), e2200043. DOI Scopus2
2022	Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Keefe, D. M., & Bowen, J. M. (2022). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats. Neoplasia, 30, 100806-1-100806-10. DOI Scopus9 WoS4 Europe PMC6
2022	Delany, C., Milch, V., Keefe, D., & Wong, Z. W. (2022). COVID-19 recovery: implications for cancer care clinicians. Supportive Care in Cancer, 30(2), 1003-1006. DOI Scopus2 WoS3 Europe PMC2
2022	Araújo, R. S., Oliveira, M. C., Cardoso, V. N., Keefe, D. M. K., & Stringer, A. M. (2022). The effect of free and encapsulated cisplatin into long-circulating and pH-sensitive liposomes on IEC-6 cells during wound healing in the presence of host–microbiota. Journal of Pharmacy and Pharmacology, 74(5), 711-717. DOI
2022	Butler, T., Gall, A., Garvey, G., Ngampromwongse, K., Hector, D., Turnbull, S., . . . Anderson, K. (2022). A Comprehensive Review of Optimal Approaches to Co-Design in Health with First Nations Australians. International Journal of Environmental Research and Public Health, 19(23), 1-38. DOI Scopus23 Europe PMC12
2022	Wardill, H. R., Chan, R. J., Chan, A., Keefe, D., Costello, S. P., & Hart, N. H. (2022). Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations.. Support Care Cancer, 30(8), 6369-6373. DOI Scopus7 WoS6 Europe PMC6
2021	Milch, V., Aranda, S., Canfell, K., Varlow, M., Roder, D. M., Currow, D., . . . Keefe, D. (2021). Overdiagnosis of screen-detected breast cancer. Medical Journal of Australia, 214(10), 455-456.e1. DOI Scopus1 Europe PMC1
2021	Milch, V., Hector, D., Turnbull, S., Sathiaraj, R., Jackson, P., Anderiesz, C., & Keefe, D. (2021). Cancer Australia's Response to the COVID-19 Pandemic. Clinical Oncology, 33(1), e58-e60. DOI Europe PMC1
2021	Milch, V., Wang, R., Der Vartanian, C., Austen, M., Hector, D., Anderiesz, C., & Keefe, D. (2021). Cancer Australia consensus statement on COVID-19 and cancer care: embedding high value changes in practice. Medical Journal of Australia, 215(10), 479-484. DOI Scopus8 Europe PMC4
2021	Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Keefe, D. M., & Bowen, J. M. (2021). Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.. Breast Cancer, 28(1), 99-109. DOI Scopus8 WoS3 Europe PMC6
2020	Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., . . . Zur, E. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19), 4423-4431. DOI Scopus324 WoS208 Europe PMC159
2020	Wan Mohamad Zain, W. N. I. Z., Bowen, J., Bateman, E., & Keefe, D. (2020). Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines.. Biomedicines, 8(1), 14 pages. DOI Scopus4 WoS3 Europe PMC3
2020	Mayo, B., Secombe, K., Wignall, A., Bateman, E., Thorpe, D., Pietra, C., . . . Bowen, J. (2020). The GLP-2 Analogue Elsiglutide Reduces Diarrhoea Caused by the Tyrosine Kinase Inhibitor Lapatinib in Rats. Cancer Chemotherapy and Pharmacology, 85(4), 793-803. DOI Scopus16 WoS12 Europe PMC11
2020	Olver, I., Keefe, D., Herrstedt, J., Warr, D., Roila, F., & Ripamonti, C. I. (2020). Supportive care in cancer-a MASCC perspective.. Support Care Cancer, 28(8), 3467-3475. DOI Scopus61 WoS36 Europe PMC31
2020	Chiam, K., Mayne, G. C., Wang, T., Watson, D. I., Irvine, T. S., Bright, T., . . . Hussey, D. J. (2020). Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus. World Journal of Gastroenterology, 26(20), 2570-2583. DOI Scopus15 WoS11 Europe PMC15
2020	Roder, D., Selva-Nayagam, S., Paramasivam, S., Keefe, D., Olver, I., Miller, C., . . . Oehler, M. (2020). Cancers of the corpus uteri treated in South Australian public hospitals: Trends in clinical management and survival across three decades.. Eur J Cancer Care (Engl), 29(5), 1-12. DOI
2019	Li, M., Olver, I., Keefe, D., Holden, C., Worthley, D., Price, T., . . . Roder, D. (2019). Pre-diagnostic colonoscopies reduce cancer mortality - Results from linked population-based data in South Australia. BMC Cancer, 19(1), 856. DOI Scopus10 WoS4 Europe PMC1
2019	Tarricone, R., Cucciniello, M., Armeni, P., Petracca, F., Desouza, K. C., Hall, L. K., & Keefe, D. (2019). Mobile Health Divide Between Clinicians and Patients in Cancer Care: Results From a Cross-Sectional International Survey. JMIR MHEALTH AND UHEALTH, 7(9), 16 pages. DOI Scopus21 WoS13 Europe PMC14
2019	Keefe, D. M. K., & Bateman, E. H. (2019). Potential Successes and Challenges of Targeted Cancer Therapies. Journal of the National Cancer Institute. Monographs, 2019(53), lgz008. DOI Scopus28 Europe PMC15
2019	Lalla, R. V., Brennan, M. T., Gordon, S. M., Sonis, S. T., Rosenthal, D. I., & Keefe, D. M. (2019). Oral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation Therapy. Journal of the National Cancer Institute. Monographs, 2019(53), lgz011. DOI Scopus87 Europe PMC38
2019	Roder, D., Karapetis, C. S., Olver, I., Keefe, D., Padbury, R., Moore, J., . . . Price, T. (2019). Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival.. BMJ open, 9(9), 1-11. DOI Scopus24 WoS16 Europe PMC14
2019	Tarricone, R., Cucciniello, M., Armeni, P., Petracca, F., Desouza, K. C., Hall, L. K., & Keefe, D. (2019). Mobile Health Divide Between Clinicians and Patients in Cancer Care: Results From a Cross-Sectional International Survey (Preprint). DOI
2019	Roder, D., Davy, M., Selva-Nayagam, S., Paramasivam, S., Adams, J., Keefe, D., . . . Oehler, M. K. (2019). Exploring the added value of hospital-registry data for showing local service outcomes: Cancers of the ovary, fallopian tube and peritoneum. BMJ Open, 9(2), e024036. DOI Scopus1 WoS1
2019	Banham, D., Roder, D., Keefe, D., Farshid, G., Eckert, M., Howard, N., . . . Brown, A. (2019). Disparities in breast screening, stage at diagnosis, cancer treatment and the subsequent risk of cancer death: a retrospective, matched cohort of aboriginal and non-aboriginal women with breast cancer. BMC Health Services Research, 19(1), 387-1-387-11. DOI Scopus18 WoS15 Europe PMC10
2019	Bowen, J. M., Gibson, R. J., Coller, J. K., Blijlevens, N., Bossi, P., Al-Dasooqi, N., . . . Elad, S. (2019). Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Supportive Care in Cancer, 27(10), 4011-4022. DOI Scopus58 WoS40 Europe PMC27
2019	Secombe, K., Ball, I., Shirren, J., Wignall, A., Finnie, J., Keefe, D., . . . Bowen, J. (2019). Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model. Cancer Chemotherapy and Pharmacology, 83(3), 531-543. DOI Scopus14 WoS8 Europe PMC10
2019	Lee, A., Bowen, J., Su, Y., Plews, E., Chung, R., Keefe, D. M., & Xian, C. (2019). Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats. Journal of Cellular Biochemistry, 120(3), 4180-4191. DOI Scopus4 WoS2 Europe PMC4
2019	Ahmedzai, S. H., Bautista, M. J., Bouzid, K., Gibson, R., Gumara, Y., Hassan, A. A. I., . . . Wang, J. J. (2019). Optimizing cancer pain management in resource-limited settings. Supportive Care in Cancer, 27(6), 2113-2124. DOI Scopus14 WoS12 Europe PMC11
2018	Stansborough, R. L., Al-Dasooqi, N., Bateman, E. H., Bowen, J. M., Keefe, D. M. K., Logan, R. M., . . . Gibson, R. J. (2018). Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo. Supportive Care in Cancer, 26(11), 3873-3882. DOI Scopus7 WoS7 Europe PMC4
2018	Stansborough, R. L., Bateman, E. H., Al-Dasooqi, N., Bowen, J. M., Wignall, A., Keefe, D. M., . . . Gibson, R. J. (2018). Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. International Journal of Radiation Biology, 94(7), 645-655. DOI Scopus6 WoS4 Europe PMC4
2018	Roder, D., Davy, M., Selva-Nayagam, S., Paramasivam, S., Adams, J., Keefe, D., . . . Oehler, M. (2018). Using hospital registries in Australia to extend data availability on vulval cancer treatment and survival. BMC Cancer, 18(1), 10 pages. DOI Scopus5 WoS5 Europe PMC3
2018	Jordan, K., Aapro, M., Kaasa, S., Ripamonti, C., Scotté, F., Strasser, F., . . . Cervantes, A. (2018). European Society for Medical Oncology (ESMO) position paper on supportive and palliative care.. Annals of Oncology, 29(1), 36-43. DOI Scopus219 WoS170 Europe PMC122
2018	Van Sebille, Y., Gibson, R., Wardill, H., Ball, I., Keefe, D., & Bowen, J. (2018). Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. International Journal of Cancer, 142(2), 369-380. DOI Scopus13 WoS12 Europe PMC11
2018	Allen, G., Logan, R., Revesz, T., Keefe, D., & Gue, S. (2018). The prevalence and investigation of risk factors of oral mucositis in a pediatric oncology inpatient population; a prospective study. Journal of Pediatric Hematology/Oncology, 40(1), 15-21. DOI Scopus29 WoS23 Europe PMC10
2017	Roder, D., Davy, M., Selva-Nayagam, S., Gowda, R., Paramasivam, S., Adams, J., . . . Oehler, M. (2017). The value of local registry data for describing cervical cancer management and outcomes over three decades in Australia. European Journal of Cancer Care, 27(1), e12760-1-e12760-14. DOI
2017	Roder, D., Farshid, G., Kollias, J., Koczwara, B., Karapetis, C., Adams, J., . . . Price, T. (2017). Female breast cancer management and survival: the experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly. Journal of Evaluation in Clinical Practice, 23(6), 1433-1443. DOI Scopus5 WoS5 Europe PMC3
2017	Banham, D., Roder, D., Keefe, D., Farshid, G., Eckert, M., Cargo, M., & Brown, A. (2017). Disparities in cancer stage at diagnosis and survival of Aboriginal and non-Aboriginal South Australians. Cancer Epidemiology, 48, 131-139. DOI Scopus19 WoS19 Europe PMC14
2017	Fan, C., Georgiou, K., Morris, H., McKinnon, R., Keefe, D., Howe, P., & Xian, C. (2017). Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model. Breast Cancer Research and Treatment, 165(1), 41-51. DOI Scopus38 WoS29 Europe PMC24
2017	Stansborough, R., Bateman, E., Al-Dasooqi, N., Bowen, J., Keefe, D., Yeoh, A., . . . Gibson, R. (2017). Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity. Supportive Care in Cancer, 25(6), 1973-1983. DOI Scopus14 WoS13 Europe PMC12
2017	Kim, D., Garon, E., Jatoi, A., Keefe, D., Lacouture, M., Sonis, S., . . . Cho, B. (2017). Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer, 106, 76-82. DOI Scopus12 WoS11 Europe PMC5
2017	Buckley, E., Farshid, G., Gill, G., Kollias, J., Koczwara, B., Karapetis, C., . . . Roder, D. (2017). Assessing impact of organised breast screening across small residential areas-development and internal validation of a prediction model. European Journal of Cancer Care, 26(4), e12673-1-e12673-8. DOI
2017	Van Sebille, Y., Gibson, R., Wardill, H., Secombe, K., Ball, I., Keefe, D., . . . Bowen, J. (2017). Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. International Journal of Cancer, 140(12), 2820-2829. DOI Scopus27 WoS22 Europe PMC21
2017	Roder, D., Farshid, G., Gill, G., Kollias, J., Koczwara, B., Karapetis, C., . . . Beckmann, K. (2017). Breast cancer screening-opportunistic use of registry and linked screening data for local evaluation. Journal of Evaluation in Clinical Practice, 23(3), 508-516. DOI Scopus4 WoS2 Europe PMC2
2017	Al-Dasooqi, N., Bowen, J., Bennett, C., Finnie, J., Keefe, D., & Gibson, R. (2017). Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study. Supportive Care in Cancer, 25(2), 391-398. DOI Scopus6 WoS5 Europe PMC3
2017	Mayo, B., Stringer, A., Bowen, J., Bateman, E., & Keefe, D. (2017). Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues. Cancer Chemotherapy and Pharmacology, 79(2), 233-249. DOI Scopus17 WoS13 Europe PMC11
2017	Campbell, J., Stephenson, M., Bateman, E., Peters, M., Keefe, D., & Bowen, J. (2017). Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics Journal, 17(1), 21-28. DOI Scopus53 WoS44 Europe PMC30
2016	Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2016). Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly. European Journal of Cancer Care, 25(5), 753-763. DOI Scopus4 WoS4 Europe PMC4
2016	Keefe, D., Al Garni, A., Villalon, A., Hassan, A., Kwong, D., Li, P., . . . Aapro, M. (2016). Challenges in supportive cancer care: perspectives from the Asia Pacific and Middle East. Supportive Care in Cancer, 24(11), 4479-4481. DOI Scopus8 WoS8 Europe PMC5
2016	Bala, V., Rao, S., Bateman, E., Keefe, D., Wang, S., & Prestidge, C. (2016). Enabling oral SN38-based chemotherapy with a combined lipophilic prodrug and self-microemulsifying drug delivery system. Molecular Pharmaceutics, 13(10), 3518-3525. DOI Scopus42 WoS41 Europe PMC12
2016	Hu, Z., Liang, W., Yang, Y., Keefe, D., Ma, Y., Zhao, Y., . . . Zhang, L. (2016). Personalized estimate of chemotherapy-induced nausea and vomiting: development and external validation of a nomogram in cancer patients receiving highly/moderately emetogenic chemotherapy. Medicine, 95(2), e2476-1-e2476-6. DOI Scopus26 WoS18 Europe PMC18
2016	Allen, G., Revesz, T., Logan, R., Keefe, D., & Gue, S. (2016). The development of an evidenced-based and clinically trialled Oral Health Protocol for Paediatric Oncology Patients at the Women’s and Children’s Hospital, Adelaide, South Australia. Supportive Care in Cancer, 24(5), 1933-1934. DOI Scopus1 WoS1 Europe PMC1
2016	Stansborough, R., Al-dasooqi, N., Bateman, E., Keefe, D., & Gibson, R. (2016). Radiotherapy-induced gut toxicity: involvement of matrix metalloproteinases and the intestinal microvasculature. International Journal of Radiation Biology, 92(5), 241-248. DOI Scopus14 WoS11 Europe PMC8
2016	Ruhlmann, C., Christensen, T., Dohn, L., Paludan, M., Rønnengart, E., Halekoh, U., . . . Herrstedt, J. (2016). Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. The Lancet Oncology, 17(4), 509-518. DOI Scopus39 WoS33 Europe PMC21
2016	Bateman, E. H., & Keefe, D. M. K. (2016). How can eHealth enhance adherence to cancer therapy and supportive care?. Srpski Arhiv za Celokupno Lekarstvo, 144(1-2), 116-121. DOI Scopus8 Europe PMC6
2016	Lacouture, M., Keefe, D., Sonis, S., Jatoi, A., Gernhardt, D., Wang, T., . . . Garon, E. (2016). A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Annals of Oncology, 27(9), 1712-1718. DOI Scopus53 WoS39 Europe PMC35
2016	Bateman, E., Weaver, E., Klein, G., Wignall, A., Wozniak, B., Plews, E., . . . Keefe, D. (2016). Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis. Supportive Care in Cancer, 24(1), 377-385. DOI Scopus9 WoS9 Europe PMC9
2015	Fan, C., Georgiou, K. R., McKinnon, R. A., Keefe, D. M. K., Howe, P. R. C., & Xian, C. J. (2015). Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats. Journal of Bone and Mineral Metabolism, 34(3), 277-290. DOI Scopus30 WoS27 Europe PMC21
2015	Perez, D., Sharples, K., Broom, R., Jeffery, M., Proctor, J., Hinder, V., . . . Findlay, M. (2015). A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhoea. Supportive Care in Cancer, 23(11), 3307-3315. DOI Scopus8 WoS6 Europe PMC5
2015	Bowen, J., White, I., Smith, L., Tsykin, A., Kristaly, K., Thompson, S., . . . Keefe, D. (2015). Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. Supportive Care in Cancer, 23(11), 3165-3172. DOI Scopus9 WoS6 Europe PMC7
2015	Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2015). Colorectal cancer treatment and survival : the experience of major public hospitals in South Australia over three decades. Asian Pacific Journal of Cancer Prevention, 16(6), 2431-2440. DOI Scopus27 Europe PMC17
2015	Chiam, K., Wang, T., Watson, D., Mayne, G., Irvine, T., Bright, T., . . . Hussey, D. (2015). Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. Journal of Gastrointestinal Surgery, 19(7), 1208-1215. DOI Scopus119 WoS107 Europe PMC90
2015	Vanhoecke, B., Bateman, E., Mayo, B., Vanlancker, E., Stringer, A., Thorpe, D., & Keefe, D. (2015). Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. Experimental Biology and Medicine, 240(6), 725-741. DOI Scopus25 WoS19 Europe PMC10
2015	Chan, A., Kim, H., Hsieh, R., Yu, S., de Lima Lopes, G., Su, W., . . . Keefe, D. (2015). Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice—a longitudinal analysis. Supportive Care in Cancer, 23(1), 283-291. DOI Scopus29 WoS25 Europe PMC16
2015	Yu, S., Burke, T., Chan, A., Kim, H., Hsieh, R., Hu, X., . . . Keefe, D. (2015). Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy-a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Supportive Care in Cancer, 23(1), 273-282. DOI Scopus28 WoS23 Europe PMC24
2015	Sonis, S., Elting, L., Keefe, D., Nguyen, H., Grunberg, S., Randolph-Jackson, P., & Brennan, M. (2015). Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. Supportive Care in Cancer, 23(2), 433-439. DOI Scopus15 WoS12 Europe PMC10
2015	Vanhoecke, B., De Ryck, T., Stringer, A., Van de Wiele, T., & Keefe, D. (2015). Microbiota and their role in the pathogenesis of oral mucositis. Oral Diseases, 21(1), 17-30. DOI Scopus85 WoS53 Europe PMC54
2015	Al-Azri, A. R., Gibson, R. J., Bowen, J. M., Stringer, A. M., Keefe, D. M., & Logan, R. M. (2015). Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. Journal of Oral Pathology & Medicine, 44(6), 459-467. DOI Scopus29 WoS28 Europe PMC16
2015	Kim, H., Hsieh, R., Chan, A., Yu, S., Han, B., Gao, Y., . . . Keefe, D. (2015). Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Supportive Care in Cancer, 23(1), 293-300. DOI Scopus20 WoS16 Europe PMC14
2015	Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., . . . Elad, S. (2015). Erratum: MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy (Cancer (2014) 120 (1453-1661)). Cancer, 121(8), 1339. DOI WoS2
2015	Bessen, T., Keefe, D. M. K., & Karnon, J. (2015). Does one size fit all? Cost utility analyses of alternative mammographic follow-up schedules, by risk of recurrence. International Journal of Technology Assessment in Health Care, 31(5), 281-288. DOI Scopus9 WoS7 Europe PMC7
2015	Campbell, J., Bateman, E., Stephenson, M., Bowen, J., Keefe, D., & Peters, M. D. (2015). Methotrexate-induced Toxicity Pharmacogenetics; an Umbrella Review of Systematic reviews and Meta-analyses. Tumor Biology: from basic science to clinical application, 78(1), 27-39. DOI Scopus51 WoS42 Europe PMC20
2015	Campbell, J., Bateman, E., Peters, M. D., Bowen, J., Keefe, D., & Stephenson, M. (2015). Fluoropyrimidine and Platinum Toxicity Pharmacogenetics: an Umbrella Review of Systematic reviews and Meta-analyses. FutureMedicine Pharmacogenomics, 17(4), 435-451. DOI Scopus32 WoS20 Europe PMC19
2015	Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2015). Metastatic colorectal cancer treatment and survival: the experience of major public hospitals in South Australia over three decades. Asian Pacific Journal of Cancer Prevention, 16(14), 5923-5931. DOI Scopus12 Europe PMC2
2015	Van Sebille, Y., Stansborough, R., Wardill, H., Bateman, E., Gibson, R., & Keefe, D. (2015). Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Current Oncology Reports, 17(11), 50-1-50-8. DOI Scopus63 WoS52 Europe PMC29
2015	Peeters, S., Engelen, L., Buijs, J., Chaturvedi, N., Fuller, J., Schalkwijk, C., . . . EURODIAB Prospective Complications Study Group. (2015). Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: The EURODIAB Prospective Complications Study. Cardiovascular Diabetology, 14(1), 31-1-31-10. DOI Scopus51 Europe PMC34
2014	Laven, G., Keefe, D., Duggan, P., & Tonkin, A. (2014). How was the intern year?: self and clinical assessment of four cohorts, from two medical curricula. BMC Medical Education, 14(1), 123-1-123-10. DOI Scopus4 WoS5 Europe PMC4
2014	Keefe, D., Elting, L., Nguyen, H., Grunberg, S., Aprile, G., Bonaventura, A., . . . Sonis, S. (2014). Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. Cancer Chemotherapy and Pharmacology, 74(4), 675-680. DOI Scopus31 WoS26 Europe PMC19
2014	Hsieh, R., Chan, A., Kim, H., Yu, S., Kim, J., Lee, M., . . . Keefe, D. (2014). Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Supportive Care in Cancer, 23(1), 263-272. DOI Scopus44 WoS42 Europe PMC33
2014	Khaw, A., Liberali, S., Logan, R., Keefe, D., & Bartold, P. (2014). Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study. Supportive Care in Cancer, 22(8), 2119-2125. DOI Scopus16 WoS11 Europe PMC8
2014	Keefe, D., Chan, A., Kim, H., Hsieh, R., Yu, S., Wang, Y., . . . Burke, T. (2014). Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. Supportive Care in Cancer, 23(1), 253-261. DOI Scopus7 WoS5 Europe PMC6
2014	Bessen, T., Chen, G., Street, J., Eliott, J., Karnon, J., Keefe, D., & Ratcliffe, J. (2014). What sort of follow-up services would Australian breast cancer survivors prefer if we could no longer offer long-term specialist-based care? A discrete choice experiment. British Journal of Cancer, 110(4), 859-867. DOI Scopus33 WoS28 Europe PMC20
2014	Bowen, J., Mayo, B., Plews, E., Bateman, E., Wignall, A., Stringer, A., . . . Keefe, D. (2014). Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemotherapy and Pharmacology, 74(3), 617-627. DOI Scopus23 WoS17 Europe PMC15
2014	Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., . . . The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). (2014). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 120(10), 1453-1461. DOI Scopus835 WoS619 Europe PMC477
2014	Chan, A., Lees, J., & Keefe, D. (2014). The changing paradigm for supportive care in cancer patients. Supportive Care in Cancer, 22(6), 1441-1445. DOI Scopus9 WoS5 Europe PMC3
2013	Khaw, A., Logan, R., Keefe, D., & Bartold, M. (2013). Radiation-induced oral mucositis and periodontitis - proposal for an inter-relationship. Oral Diseases, 20(3), e7-e18. DOI Scopus45 WoS32 Europe PMC25
2013	Al-Azri, A., Gibson, R., Keefe, D., & Logan, R. (2013). Matrix metalloproteinases: do they play a role in mucosal pahology of the oral cavity?. Oral Diseases, 19(4), 347-359. DOI Scopus19 WoS14 Europe PMC12
2013	Qutob, A., Allen, G., Gue, S., Revesz, T., Logan, R., & Keefe, D. (2013). Implementation of a hospital oral care protocol and recording of oral mucositis in children receiving cancer treatment: a retrospective and a prospective study. Supportive Care in Cancer, 21(4), 1113-1120. DOI Scopus35 WoS30 Europe PMC18
2013	Stringer, A., Al-Dasooqi, N., Bowen, J., Tan, T., Radzuan, M., Logan, R., . . . Gibson, R. (2013). Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Supportive Care in Cancer, 21(7), 1843-1852. DOI Scopus104 WoS94 Europe PMC74
2013	Qutob, A., Gue, S., Revesz, T., Logan, R., & Keefe, D. (2013). Prevention of oral mucositis in children receiving cancer therapy: a systematic review and evidence-based analysis. Oral Oncology, 49(2), 102-107. DOI Scopus58 WoS54 Europe PMC34
2013	Gibson, R., Keefe, D., Lalla, R., Bateman, E., Blijlevens, N., Fijlstra, M., . . . Bowen, J. (2013). Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Supportive Care in Cancer, 21(1), 313-326. DOI Scopus175 WoS152 Europe PMC109
2013	Bateman, E., Bowen, J., Stringer, A., Mayo, B., Plews, E., Wignall, A., . . . Keefe, D. (2013). Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model. Nutrients, 5(10), 3948-3963. DOI Scopus9 WoS9 Europe PMC8
2013	Lang, S., Keefe, D., Schultz, T., & Pearson, A. (2013). Predictors of acute adverse events from rapid rituximab infusion. Supportive Care in Cancer, 21(8), 2315-2320. DOI Scopus11 WoS5 Europe PMC9
2012	Bowen, J., Mayo, B., Plews, E., Bateman, E., Stringer, A., Boyle, F., . . . Keefe, D. (2012). Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biology & Therapy, 13(13), 1269-1275. DOI Scopus31 WoS28 Europe PMC28
2012	Keefe, D., & Bateman, E. (2012). Tumor control versus adverse events with targeted anticancer therapies. Nature Reviews Clinical Oncology, 9(2), 98-109. DOI Scopus90 Europe PMC42
2012	Niscola, P., Tendas, A., Cupelli, L., Catalano, G., Scaramucci, L., Giovannini, M., . . . Keefe, D. (2012). The prevention of oral mucositis in patients with blood cancers: current concepts and emerging landscapes. Cardiovascular and Hematological Agents in Medicinal Chemistry, 10(4), 362-375. DOI Scopus4 Europe PMC3
2011	Bowen, J., Gibson, R., & Keefe, D. (2011). Animal models of mucositis: Implications for therapy. The Journal of Supportive Oncology, 9(5), 161-168. DOI Scopus56 Europe PMC37
2011	Al-Dasooqi, N., Bowen, J., Gibson, R., Logan, R., Stringer, A., & Keefe, D. (2011). Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. International Journal of Experimental Pathology, 92(5), 357-365. DOI Scopus36 WoS30 Europe PMC28
2011	Bateman, E., & Keefe, D. (2011). Patient-reported outcomes in supportive care. Seminars in Oncology, 38(3), 358-361. DOI Scopus14 WoS12 Europe PMC10
2011	Keefe, D., Bowen, J., Gibson, R., Tan, T., Okera, M., & Stringer, A. (2011). Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. The Oncologist, 16(4), 432-444. DOI Scopus82 WoS62 Europe PMC42
2011	Al-Dasooqi, N., Bowen, J., Gibson, R., Logan, R., Stringer, A., & Keefe, D. (2011). Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy, 57(1), 43-53. DOI Scopus14 WoS14 Europe PMC10
2010	Al-Dasooqi, N., Gibson, R., Bowen, J., Logan, R., Stringer, A., & Keefe, D. (2010). Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Experimental Biology and Medicine (Maywood), 235(10), 1244-1256. DOI Scopus58 WoS48 Europe PMC42
2010	Ong, Z., Gibson, R., Bowen, J., Stringer, A., Darby, J., Logan, R., . . . Keefe, D. (2010). Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiation Oncology, 5(22), 1-8. DOI Scopus115 WoS100 Europe PMC71
2010	Bowen, J., Tsykin, A., Stringer, A., Logan, R., Gibson, R., & Keefe, D. (2010). Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. Toxicology, 269(1), 1-12. DOI Scopus11 WoS8 Europe PMC7
2010	Keefe, D., & Bateman, E. (2010). Gastrointestinal toxicity of targeted anti-cancer therapy. Treatment Stragegies Oncology, 2010, 224-227.
2010	Lalla, R., Pilbeam, C., Walsh, S., Sonis, S., Keefe, D., & Peterson, D. (2010). Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Supportive Care in Cancer, 18(1), 95-103. DOI Scopus42 Europe PMC26
2010	Al-Dasooqi, N., Gibson, R., Bowen, J., Logan, R., Stringer, A., & Keefe, D. (2010). Matrix metalloproteinases and their inhibitors are altered in a time-course model of irinotecan-induced mucositis. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 25(s3), A2. DOI
2010	Keefe, D., & Stringer, A. (2010). Editorial: The potential successes and challenges of targeted anticancer therapies. Current Opinion in Supportive and Palliative Care, 4(1), 16-18. DOI Scopus4 Europe PMC4
2009	Aprile, G., Ramoni, M., Keefe, D., & Sonis, S. (2009). Links between regimen-related toxicities in patients being treated for colorectal cancer. Current Opinion in Supportive and Palliative Care, 3(1), 50-54. DOI Scopus14 Europe PMC14
2009	Keefe, D. M. (2009). Mucositis and lung cancer. JOURNAL OF THORACIC ONCOLOGY, 4(9), S36.
2009	Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Al-Dasooqi, N., & Keefe, D. M. K. (2009). The importance of the gut microbiome in gastrointestinal mucositis. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 24, A237.
2009	Al-Dasooqi, N., Bowen, J., Gibson, R., Sullivan, T., Lees, J., & Keefe, D. (2009). Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Investigational New Drugs, 27(2), 173-178. DOI Scopus26 WoS14 Europe PMC15
2009	Al-Dasooqi, N., Gibson, R., Bowen, J., & Keefe, D. (2009). HER2 targeted therapies for cancer and the gastrointestinal tract. Current Drug Targets, 10(6), 537-542. DOI Scopus18 WoS17 Europe PMC11
2009	Al-Dasooqi, N., Gibson, R., Bowen, J., & Keefe, D. (2009). Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?. Cancer Chemotherapy and Pharmacology, 64(1), 1-9. DOI Scopus39 WoS37 Europe PMC23
2009	Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., Hamilton, J., & Keefe, D. (2009). Gastrointestinal Microflora and Mucins May Play a Critical Role in the Development of 5-Fluorouracil-Induced Gastrointestinal Mucositis. Experimental Biology and Medicine (Maywood), 234(4), 430-441. DOI Scopus185 WoS158 Europe PMC106
2009	Stringer, A., Gibson, R., Bowen, J., & Keefe, D. (2009). Chemotherapy-induced modifications to gastrointestinal microflora: Evidence and implications of change. Current Drug Metabolism, 10(1), 79-83. DOI Scopus95 WoS83 Europe PMC61
2009	Stringer, A., Gibson, R., Bowen, J., Logan, R., Ashton, K., Yeoh, A., . . . Keefe, D. (2009). Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. International Journal of Experimental Pathology, 90(5), 489-499. DOI Scopus123 WoS104 Europe PMC79
2009	Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., Laurence, J., & Keefe, D. (2009). Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemotherapy and Pharmacology, 64(1), 123-132. DOI Scopus69 WoS63 Europe PMC47
2009	Logan, R., Stringer, A., Bowen, J., Gibson, R., Sonis, S., & Keefe, D. (2009). Is the pathobiology of chemotherapy-induced alimentary tract mucositis inXuenced by the type of mucotoxic drug administered?. Cancer Chemotherapy and Pharmacology, 63(2), 239-251. DOI Scopus142 WoS124 Europe PMC93
2008	Aprile, G., Ramoni, M., Keefe, D., & Sonis, S. (2008). Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer, 112(2), 284-292. DOI Scopus55 WoS40 Europe PMC40
2008	Keefe, D., & Prowse, R. (2008). Geriatric oncology: A medical sub-specialty whose time has come. Cancer Forum, 32(1), 3-5. Scopus2 WoS2
2008	Elting, L., Keefe, D., Sonis, S., Garden, A., Spijkervet, F., Barasch, A., . . . Vera-Llonch, M. (2008). Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: Demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer, 113(10), 2704-2713. DOI Scopus288 WoS228 Europe PMC176
2008	Niscola, P., Scaramucci, L., Romani, C., Cupelli, L., Tendas, A., Dentamaro, T., . . . de Fabritiis, P. (2008). Mucositis in the treatment of haematological malignancies. Annals of Oncology, 19(Supp 7), 141-145. DOI Scopus5 WoS5 Europe PMC4
2008	Keefe, D., Sonis, S., & Bowen, J. (2008). Emerging drugs for chemotherapy-induced mucositis. Expert Opinion on Emerging Drugs, 13(3), 511-522. DOI Scopus42 WoS37 Europe PMC25
2008	Logan, R., Stringer, A., Bowen, J., Gibson, R., Sonis, S., & Keefe, D. (2008). Serum levels of NF kappa B and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biology & Therapy, 7(7), 1139-1145. DOI Scopus151 WoS124 Europe PMC99
2008	Gibson, R., Bowen, J., & Keefe, D. (2008). Technological advances in mucositis research: New insights and new issues. Cancer Treatment Reviews, 34(5), 476-482. DOI Scopus17 WoS15 Europe PMC8
2008	Bowen, J., & Keefe, D. (2008). New pathways for alimentary mucositis. Journal of Oncology, 2008, 1-7. DOI WoS21 Europe PMC8
2008	Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., & Keefe, D. (2008). Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biology & Therapy, 7(12), 1919-1925. DOI Scopus157 WoS125 Europe PMC100
2008	Logan, R., Gibson, R., Bowen, J., Stringer, A., Sonis, S., & Keefe, D. (2008). Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemotherapy and Pharmacology, 62(1), 33-41. DOI Scopus161 WoS142 Europe PMC129
2008	Keefe, D., & Anthony, L. (2008). Tyrosine kinase inhibitors and gut toxicity: A new era in supportive care. Current Opinion in Supportive and Palliative Care, 2(1), 19-21. DOI Scopus11 Europe PMC9
2008	Barasch, A., Spijkervet, F., Garden, A., Kudrimoti, M. R., Brachman, D., Brennan, M., . . . Sonis, S. (2008). Efficacy of opioid analgesics and effect on functional status of pain caused by radiation-induced mucositis among patients with head and neck cancer. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. DOI WoS2
2008	Niscola, P., Scaramucci, L., Romani, C., Cupelli, L., Tendas, A., Dentamaro, T., . . . de Fabritiis, P. (2008). Erratum: Mucositis in the treatment of haematological malignancies (Annals of Oncology (2008) vol. 19 (vii141-vii145)). Annals of Oncology, 19(11), 1982. DOI
2007	Keefe, D. M. K. (2007). Supportive care silos: time to forge cross-links, using mucositis as an example.. Current opinion in supportive and palliative care, 1(1), 40-42. DOI Scopus2 Europe PMC2
2007	Logan, R., Gibson, R., Sonis, S., & Keefe, D. (2007). Nuclear factor-κ B (NF-κ B) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncology, 43(4), 395-401. DOI Scopus137 WoS115 Europe PMC97
2007	Keefe, D., Schubert, M., Elting, L., Sonis, S., Epstein, J., Raber-Durlacher, J., . . . Peterson, D. (2007). Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer, 109(5), 820-831. DOI Scopus639 WoS501 Europe PMC393
2007	Bowen, J., Gibson, R., Stringer, A., Chan, T., Prabowo, A., Cummins, A., & Keefe, D. (2007). Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anti-Cancer Drugs, 18(2), 197-210. DOI Scopus23 WoS20 Europe PMC16
2007	Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., Burns, J., & Keefe, D. (2007). Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Experimental Biology and Medicine (Maywood), 232(1), 96-106. Scopus95 WoS73 Europe PMC47
2007	Jones, A., Wilson, I., & Keefe, D. (2007). Developing a Process of Continuous Quality Improvement in Medical School Assessment Processes: Lessons from One School. Focus on Health Professional Education, 9(2), 39-46.
2007	Bowen, J., Stringer, A., Gibson, R., Yeoh, A., Hannam, S., & Keefe, D. (2007). VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss. Cancer Biology & Therapy, 6(9), 1449-1454. DOI Scopus168 WoS145 Europe PMC100
2007	Keefe, D., Rassias, G., O'Neil, L., & Gibson, R. (2007). Severe mucositis: How can nutrition help?. Current Opinion in Clinical Nutrition and Metabolic Care, 10(5), 627-631. DOI Scopus20 WoS21 Europe PMC16
2007	Stringer, A., Gibson, R., Bowen, J., Logan, R., Yeoh, A., & Keefe, D. (2007). Chemotherapy-induced mucositis: The role of gastrointestinal microflora and mucins in the luminal environment. The Journal of Supportive Oncology, 5(6), 259-267. Scopus71 Europe PMC41
2007	Bowen, J., Gibson, R., Cummins, A., Tyskin, A., & Keefe, D. (2007). Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemotherapy and Pharmacology, 59(3), 337-348. DOI Scopus37 WoS33 Europe PMC24
2007	Duggan, P., & Keefe, D. (2007). Paid term-time employment in undergraduate medical students at the University of Adelaide. Focus on Health Professional Education, 19(1), 58-66.
2007	Logan, R., Stringer, A., Bowen, J., Yeoh, A., Gibson, R., Sonis, S., & Keefe, D. (2007). The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treatment Reviews, 33(5), 448-460. DOI Scopus229 WoS201 Europe PMC160
2007	Bowen, J., Gibson, R., Tsykin, A., Stringer, A., Logan, R., & Keefe, D. (2007). Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. International Journal of Cancer, 121(8), 1847-1856. DOI Scopus40 WoS39 Europe PMC30
2007	Yeoh, A., Gibson, R., Yeoh, E., Bowen, J., Stringer, A., Giam, K., & Keefe, D. (2007). A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis p53 nuclear factor-kappa B COX-1 and COX-2. Molecular Cancer Therapeutics, 6(8), 2319-2327. DOI Scopus51 WoS44 Europe PMC39
2007	Gibson, R., Stringer, A., Bowen, J., Logan, R., Yeoh, A., Burns, J., . . . Keefe, D. (2007). Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biology & Therapy, 6(4), 541-547. DOI Scopus14 WoS12 Europe PMC7
2007	Keefe, D. (2007). Intestinal mucositis: mechanisms and management. Current Opinion in Oncology, 19(4), 323-327. DOI Scopus74 WoS62 Europe PMC50
2007	Joshi, R., Olver, I., Keefe, D., Marafioti, T., & Smith, K. (2007). A phase I study to assess the safety and activity of topical lovastatin (FP252S) for the prevention of chemotherapy-induced alopecia. Supportive Care in Cancer, 15(9), 1109-1112. DOI Scopus7 WoS3 Europe PMC3
2007	Gibson, R., Bowen, J., Alvarez, E., Finnie, J., & Keefe, D. (2007). Establishment of a Single-Dose Irinotecan Model of Gastrointestinal Mucositis. Chemotherapy, 53(5), 360-369. DOI Scopus58 WoS45 Europe PMC36
2007	Keefe, D., & Gibson, R. (2007). Mucosal injury from targeted anti-cancer therapy. Supportive Care in Cancer, 15(5), 483-490. DOI Scopus45 WoS33 Europe PMC28
2006	Gibson, R., & Keefe, D. (2006). Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Supportive Care in Cancer, 14(9), 890-900. DOI Scopus185 WoS145 Europe PMC114
2006	Keefe, D., Lees, J., & Horvath, N. (2006). Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience. Supportive Care in Cancer, 14(6), 580-582. DOI Scopus24 WoS25 Europe PMC17
2006	Lalla, R., Schubert, M., Bensadoun, R., & Keefe, D. (2006). Anti-inflammatory agents in the management of alimentary mucositis. Supportive Care in Cancer, 14(6), 558-565. DOI Scopus65 WoS47 Europe PMC34
2006	Bensadoun, R., Schubert, M., Lalla, R., & Keefe, D. (2006). Amifostine in the management of radiation-induced and chemo-induced mucositis. Supportive Care in Cancer, 14(6), 566-572. DOI Scopus55 WoS44 Europe PMC34
2006	Peterson, D., Keefe, D., Hutchins, R., & Schubert, M. (2006). Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice. Supportive Care in Cancer, 14(6), 499-504. DOI Scopus32 WoS22 Europe PMC22
2006	Brennan, M., von Bultzingslowen, I., Schubert, M., & Keefe, D. (2006). Alimentary mucositis: putting the guidelines into practice. Supportive Care in Cancer, 14(6), 573-579. DOI Scopus13 WoS10 Europe PMC11
2006	von Bultzingslowen, I., Brennan, M., Spijkervet, F., Logan, R., Stringer, A., Raber-Durlacher, J., & Keefe, D. (2006). Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Supportive Care in Cancer, 14(6), 519-527. DOI Scopus60 WoS49 Europe PMC40
2006	Keefe, D., Peterson, D., & Schubert, M. (2006). Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls. Supportive Care in Cancer, 14(6), 492-498. DOI Scopus22 WoS18 Europe PMC15
2006	Bowen, J., Gibson, R., Cummins, A., & Keefe, D. (2006). Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Supportive Care in Cancer, 14(7), 713-731. DOI Scopus98 WoS90 Europe PMC66
2006	Keefe, D. (2006). Supportive care in colon cancer. Supportive Cancer Therapy, 3(3), 171-172. DOI
2006	Gibson, R., Cummins, A., Bowen, J., Logan, R., Healey, T., & Keefe, D. (2006). Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. Asia Pacific Journal of Clinical Oncology, 2(1), 39-49. DOI Scopus25
2006	Keefe, D., & Gibson, R. (2006). The combination of oral and small intestinal mucositis, pediatrics and biomarkers - A particularly tricky problem!. Cancer Biology & Therapy, 5(10), 1282-1284. DOI Scopus8 WoS8 Europe PMC9
2006	Keefe, D., & Gibson, R. (2006). Sucrose breath testing and intestinal mucositis. Cancer Biology & Therapy, 5(9), 1196-1198. DOI Scopus6 WoS5 Europe PMC4
2006	Keefe, D. (2006). Mucositis guidelines: what have they achieved, and where to from here?. Supportive Care in Cancer, 14(6), 489-491. DOI Scopus26 Europe PMC15
2006	Yeoh, A., Gibson, R., Yeoh, E., Bowen, J., Stringer, A., Giam, K., . . . Keefe, D. (2006). Radiation therapy-induced mucositis: Relationships between fractionated radiation, NF-kappa B, COX-1, and COX-2. Cancer Treatment Reviews, 32(8), 645-651. DOI Scopus44 WoS38 Europe PMC24
2006	Pittman, K., Olver, I., Koczwara, B., Kotasek, D., Patterson, W., Keefe, D., . . . Price, T. (2006). Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. British Journal of Cancer, 95(10), 1309-1313. DOI Scopus32 WoS29 Europe PMC22
2006	Keefe, D. (2006). Mucositis management in patients with cancer. Supportive Cancer Therapy, 3(3), 154-157. DOI Scopus16 Europe PMC8
2006	Bowen, J. M., Gibson, R. J., Cummins, A. G., Tyskin, A., & Keefe, D. M. K. (2006). Irinotecan-induced changes in gene expression in the small intestine of the rat with cancer. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, A275.
2006	Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S. J., & Keefe, D. M. K. (2006). Chemotherapy-induced changes in mucin secretion and composition. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, A266. WoS2
2006	Yeoh, A., Gibson, R., Yeoh, E., Bowen, J., Stringer, A., Giam, K., & Keefe, D. (2006). A novel animal model to investigate radiation-induced mucositis: a qualitative assessment of mucosal injury resulting from fractionated radiotherapy. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, A260.
2005	Yeoh, A., Bowen, J., Gibson, R., & Keefe, D. (2005). Nuclear factor kB (NFkB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. International Journal of Radiation Oncology Biology Physics, 63(5), 1295-1303. DOI Scopus77 WoS66 Europe PMC57
2005	Olver, I., Keefe, D., Myers, M., & Caruso, D. (2005). A phase I study of prolonged ambulatory infusion of ifosfamide with oral mesna. Chemotherapy, 51(2-3), 142-146. DOI Scopus3 WoS2 Europe PMC1
2005	Gibson, R., Bowen, J., Cummins, A., & Keefe, D. (2005). Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clinical and Experimental Medicine, 4(4), 188-195. DOI Scopus44 WoS37 Europe PMC27
2005	Gibson, R., Bowen, J., & Keefe, D. (2005). Palifermin reduces diarrhea and increases survival following Irinotecan treatment in tumor-bearing DA rats. International Journal of Cancer, 116(3), 464-470. DOI Scopus69 WoS67 Europe PMC44
2005	Olver, I., Keefe, D., & Myers, M. (2005). Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer. Internal Medicine Journal, 35(7), 405-408. DOI Scopus5 WoS3 Europe PMC3
2005	Bowen, J., Gibson, R., Keefe, D., & Cummins, A. (2005). Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology, 37(1), 56-62. DOI Scopus73 WoS69 Europe PMC50
2004	Keefe, D. (2004). Gastrointestinal mucositis: a new biological model. Supportive Care in Cancer, 12(1), 6-9. DOI Scopus88 Europe PMC62
2004	Elting, L., Keefe, D., & Sonis, S. (2004). Treatment-Induced Gastrointestinal Toxicity in Patients With Cancer. Educational Book, 536-541.
2004	Peterson, D., Beck, S., & Keefe, D. (2004). Novel therapies. Seminars in Oncology Nursing, 20(1), 53-58. DOI Scopus12 Europe PMC8
2004	Keefe, D., Gibson, R., & Hauer-Jensen, M. (2004). Gastrointestinal mucositis. Seminars in Oncology Nursing, 20(1), 38-47. DOI Scopus93 Europe PMC62
2004	Sonis, S., Elting, L., Keefe, D., Peterson, D., Schubert, M., Hauer-Jensen, M., . . . Donelly, J. (2004). Perspectives on cancer therapy-induced mucosal injury : Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer, 100(s9), 1995-2025. DOI Scopus1197 WoS959 Europe PMC713
2004	Rubenstein, E., Peterson, D., Schubert, M., Keefe, D., McGuire, D., Epstein, J., . . . Sonis, S. (2004). Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer, 100(s9), 2026-2046. DOI Scopus650 WoS501 Europe PMC381
2003	Gibson, R., Bowen, J., Inglis, M., Cummins, A., & Keefe, D. (2003). Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. Journal of Gastroenterology and Hepatology, 18(9), 1095-1100. DOI Scopus168 WoS148 Europe PMC114
2002	Gibson, R., Keefe, D., Thompson, F., Clarke, J., Goland, G., & Cummins, A. (2002). Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Digestive Diseases and Sciences, 47(12), 2751-2757. DOI Scopus83 WoS72 Europe PMC56
2002	Gibson, R., Keefe, D., Clarke, J., Regester, G., Thompson, F., Goland, G., . . . Cummins, A. (2002). The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemotherapy and Pharmacology, 50(1), 53-58. DOI Scopus90 WoS79 Europe PMC57
2002	Olver, I., Hercus, T., Lopez, A., Vadas, M., Somogyi, A., Doyle, I., . . . Wigley, P. (2002). A phase I study of the GM-CSF antagonist E21R. Cancer Chemotherapy and Pharmacology, 50(3), 171-178. DOI Scopus8 WoS8 Europe PMC6
2000	Parnis, F., Olver, I., Kotasek, D., Norman, J., Taylor, A., Russell, J., . . . Marafioti, T. (2000). Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site. Annals of Oncology, 11(7), 883-884. DOI Scopus17 WoS16 Europe PMC14
2000	Keefe, D., Brealey, J., Goland, G., & Cummins, A. (2000). Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut, 47(5), 632-637. DOI Scopus312 WoS286 Europe PMC229
1999	Basser, R., To, L., Collins, J., Begley, C., Keefe, D., Cebon, J., . . . Green, M. (1999). Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage ii or iii breast cancer: five-year follow-up. Journal of Clinical Oncology, 17(1), 82-92. DOI Scopus20 WoS17 Europe PMC10
1999	Keefe, D. M. K., Bell, D., Wheeler, H., & Ma, D. D. F. (1999). Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancer [4]. Australian and New Zealand Journal of Medicine, 29(2), 275-277. DOI
1997	Keefe, D., Cummins, A., Dale, B., Kotasek, D., Robb, T., & Sage, R. (1997). Effect of high-dose chemotherapy on intestinal permeability in humans.. Clinical Science, 92(4), 385-389. DOI Scopus126 WoS115 Europe PMC85
1994	PATTERSON, W. K., SAGE, R. E., & KEEFE, D. M. (1994). Haemorrhagic gastritis in two patients treated with all‐trans‐retinoic acid in acute promyelocytic leukaemia. Australian and New Zealand Journal of Medicine, 24(3), 314-315. DOI Scopus1 Europe PMC1

Books

Year	Citation
2013	Sonis, S., & Keefe, D. (Eds.) (2013). Pathobiology of cancer regimen-related toxicities. United States: Springer. DOI Scopus5
2013	Sonis, S., & Keefe, D. (Eds.) (2013). Pathobiology of cancer regimen-related toxicities. United States: Springer. DOI Scopus5
2013	Al-Dasooqi, N., Keefe, D. M., & Sonis, S. T. (2013). Mucositis. DOI
2013	Al-Dasooqi, N., Keefe, D. M., & Sonis, S. T. (2013). Mucositis. DOI
2013	Sonis, S. T., & Keefe, D. M. (2013). Preface. DOI Scopus1
2013	Sonis, S. T., & Keefe, D. M. (2013). Preface. DOI Scopus1
2013	Sonis, S. T., & Keefe, D. M. (2013). Conclusion. DOI
2013	Sonis, S. T., & Keefe, D. M. (2013). Conclusion. DOI

Book Chapters

Year	Citation
2019	Bateman, E., Logan, R., Gibson, R., & Keefe, D. (2019). Mucositis. In R. MacLeod, & L. Van den Block (Eds.), Textbook of Palliative Care (pp. 1-17). Switzerland: Springer Cham.
2013	Lyng, G., Logan, R., & Mancini, M. (2013). Animal models of regimen-related toxicities. In Pathobiology of Cancer Regimen-Related Toxicities (pp. 75-95). DOI Scopus1
2013	Lyng, G., Logan, R., & Mancini, M. (2013). Animal models of regimen-related toxicities. In Pathobiology of Cancer Regimen-Related Toxicities (pp. 75-95). DOI Scopus1
2013	Al-Dasooqi, N., Keefe, D., & Sonis, S. (2013). Mucositis. In S. Sonis, & D. Keefe (Eds.), Pathobiology of Cancer Regimen-Related Toxicities (1 ed., pp. 121-146). United States: Springer.
2013	Gibson, R., Bowen, J., Bateman, E., & Keefe, D. (2013). Biology of treatment-induced mucositis. In A. Berger, J. Shuster, & J. Von Roenn (Eds.), Principles and practice of palliative oncology and supportive oncology (4th ed., pp. 238-246). Lippincott Williams & Wilkins.
2012	Al-Dasooqi, N., Gibson, R., Bowen, J., & Keefe, D. (2012). HER2 targeted therapy-induced gastrointestinal toxicity: from the clinical experience to possible molecular mechanisms. In D. Whitehouse, & R. Rapley (Eds.), Molecular and Cellular Therapeutics (1 ed., pp. 69-102). United Kingdom: Wiley. DOI
2011	Paternotte, D., Tremblay, M., & Johnson, C. (2011). Conclusion. In M. Tremblay, D. Paternotte, & C. Johnson (Eds.), The Lesbian and Gay Movement and the State: Comparative Insights into a Transformed Relationship (1 ed., pp. 213-227). United Kingdom: Ashgate Publishing Limited. DOI Scopus4
2011	Paternotte, D., Tremblay, M., & Johnson, C. (2011). Conclusion. In M. Tremblay, D. Paternotte, & C. Johnson (Eds.), The Lesbian and Gay Movement and the State: Comparative Insights into a Transformed Relationship (1 ed., pp. 213-227). United Kingdom: Ashgate Publishing Limited. DOI Scopus4
2008	Keefe, D., Bowen, J., & Gibson, R. (2008). Use of project teams in preclinical development. In S. Gad (Ed.), Preclinical Development Handbook: Toxicology (pp. 65-80). USA and Canada: Wiley. DOI
2008	Gibson, R., Bowen, J., & Keefe, D. (2008). Relationship between animal models and clinical research: using mucositis as a practical example. In S. Gad (Ed.), Preclinical Development Handbook: Toxicology (pp. 81-101). USA and Canada: Wiley. DOI Scopus1

Conference Items

Year	Citation
2021	Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Diala, I., Lalani, A. S., & Bowen, J. M. (2021). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats.. Poster session presented at the meeting of CANCER RESEARCH. Philadelphia, PA: AMER ASSOC CANCER RESEARCH.
2019	Coller, J. K., Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., . . . Bowen, J. M. (2019). Predictors of severe gastrointestinal toxicity risk in patients treated with 5-fluorouracil-based chemotherapy: A validation study. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Ruhlmann, C. H., Christensen, T. B., Dohn, L. H., Paludan, M., Roennengart, E., Hilpert, F., . . . Herrstedt, J. (2017). Fosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy: A sub-study of the GAND-emesis trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: OXFORD UNIV PRESS.
2017	Bowen, J., Ball, I., Thompson, S., Irvine, T., Chiam, K., Hussey, D., . . . Keefe, D. (2017). Identification of Inflammatory Markers of Chemoradiotherapy-Induced Gastrointestinal Toxicity in Oesophageal Cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Korver, S. K., Ball, I. A., Gibson, R. J., Logan, R. M., Karapetis, C. S., Keefe, D. M., . . . Coller, J. K. (2017). The Effect of Immune Genetic Variants on Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., Richards, A., . . . Coller, J. K. (2017). Interleukin-1 Beta (<i>IL1B</i>) Genetic Variability is Predictive of Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Bautista, M. J., Ahmedzai, S. H., Bouzid, K., Gibson, R., Gumara, Y., Hassan, A. A. I., . . . Wang, J. J. (2017). A framework for education and advocacy for optimal cancer pain management in resource-limited settings. Poster session presented at the meeting of Annals of Oncology. Singapore, SINGAPORE: OXFORD UNIV PRESS. DOI
2016	Abstracts of the MASCC/ISOO 2016 Annual Meeting. (2016). Poster session presented at the meeting of Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. Germany: Springer Science and Business Media LLC. DOI
2015	Stansborough, R. L., Bateman, E., Al-Dasooqi, N., Keefe, D., & Gibson, R. (2015). Microvascular injury and associated mediator changes occur during acute radiotherapy-induced gut toxicity. Poster session presented at the meeting of Supportive Care in Cancer. Copenhagen, Denmark: Springer Verlag (Germany).
2015	Lacouture, M. E., Keefe, D., Sonis, S. T., Giri, N., Wang, T., Reisman, A., . . . Jatoi, A. (2015). Impact of Prophylactic Doxycycline (Doxy) on Maintaining Planned Dosing of Dacomitinib (D) an Irreversible panHER Inhibitor. Poster session presented at the meeting of JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
2014	Mayo, B., Bateman, E., Stringer, A., Plews, E., Wignall, A., Wozniak, B., . . . Keefe, D. (2014). The new selective GLP-2 receptor agonist, Elsiglutide, improved irinotecan-induced diarrhoea and mucositis in the rat. Poster session presented at the meeting of Supportive Care in Cancer. Miami, USA: Springer Verlag (Germany).
2014	Mayo, B., Stringer, A., Bateman, E., Bowen, J., Pietra, C., Cantoreggi, S., & Keefe, D. (2014). Apoptosis, proliferation and inflammation are improved after treatment with the new selective GLP-2 receptor agonist, Elsiglutide, in a rat model of irinotecan-induced mucositis. Poster session presented at the meeting of Supportive Care in Cancer. Miami, USA: Springer Verlag (Germany).
2014	Keefe, D. (2014). MUCOSITIS AND ITS LINKS TO OTHER TOXICITIES IN LUNG CANCER. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2014	Mayo, B., Bateman, E., Stringer, A., Plews, E., Wignall, A., Wozniak, B., . . . Keefe, D. (2014). The new selective glp-2 receptor agonist, elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley. DOI
2014	Mayo, B., Stringer, A., Bateman, E., Bowen, J., Wignall, A., Wozniak, B., . . . Keefe, D. (2014). Apoptosis, proliferation and inflammation are improved after treatment with the new selective glp-2 receptor agonist, elsiglutide, in a rat model of irinotecan-induced mucositis. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley. DOI
2014	Bessen, T., Chen, G., Street, J., Eliott, J., Karnon, J., Keefe, D., & Ratcliffe, J. (2014). What sort of follow-up services would Australian breast cancer survivors prefer if we could no longer offer long-term specialist-based care? A discrete choice experiment. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley. DOI
2014	Fan, C., Georgiou, K. R., McKinnon, R. A., Keefe, D. M., Howe, P. R., & Xian, C. J. (2014). ADVERSE EFFECTS OF COMBINATION BREAST CANCER CHEMOTHERAPY ON BONE AND BONE MARROW. Poster session presented at the meeting of OSTEOPOROSIS INTERNATIONAL. Taipei, TAIWAN: SPRINGER LONDON LTD.
2014	Benge, S., Perez, D., Sharples, K., Broom, R., Jeffery, M., Proctor, J., . . . Findlay, M. (2014). ASSESSING THE EFFICACY OF ICE-CREAM-FORMULATED IRON-SATURATED LACTOFERRIN AND ANHYDROUS MILK FAT IN PREVENTING CHEMOTHERAPY INDUCED DIARRHOEA - THE RECHARGE STUDY, A RANDOMISED PHASE IIB TRIAL. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2013	Keefe, D., Kim, H. -K., Chan, A., Hsieh, R. K., Yu, S. Y., Hernandez, A. B., & Burke, T. (2013). CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN THE ASIA-PACIFIC (AP) REGION - THE AUSTRALIAN PERSPECTIVE FROM THE PAN-AUSTRALASIAN CHEMOTHERAPY INDUCED EMESIS STUDY (PRACTICE). Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2013	Mayo, B., Bateman, E., Stringer, A., Plews, E., Pishas, K., Pietra, C., . . . Keefe, D. (2013). The effect of the new selective GLP-2 agonist, elsiglutide, on irinotecan-induced diarrhoea and mucositis in the rat. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide Convention Centre, Adelaide, South Australia: Wiley Publishing Asia. DOI
2013	Lacouture, M., Grunberg, S., Keefe, D., Sonis, S., Ely, J., Gernhardt, D., . . . Jatoi, A. (2013). Impact of doxycycline (doxy) prophylaxis on dermatologic toxicity from dacomitinib (D) for NSCLC, by CTCAE and patient (pt)-reported outcomes (PRO) measures in a placebo-controlled trial. Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. Amsterdam, NETHERLANDS: ELSEVIER SCI LTD.
2013	Radzuan, M., Bateman, E., Bowen, J., Keefe, D., & Stringer, A. (2013). Intestinal Lactobacillus spp. increase following radiotherapy in rats: an unusual finding. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany).
2013	Bateman, E., Wilson, C., Keefe, C., Bowen, J., Wignall, A., Plews, E., & Keefe, D. (2013). Fractionated radiotherapy in a rat model causes dose-dependent changes in collagen deposition, and expression of transforming growth factor β1, Smad3 and smooth muscle actin α1. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany). DOI
2013	Mayo, B., Bateman, E., Stringer, A., Plews, E., Pishas, K., Pietra, C., . . . Keefe, D. (2013). The effect of the new selective GLP-2 agonist, Elsiglutide, on irinotecan-induced diarrhoea and mucositis in the rat.. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany). DOI
2013	Wan Mohamad Zain, W., Bowen, J., Bateman, E., & Keefe, D. (2013). Development of a walker 256-TC tumour-bearing rat model to study lapatinib-induced mucosal injury. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany). DOI
2012	Keefe, D. (2012). GASTROINTESTINAL TOXICITY IN ONCOLOGY: EVOLUTIONARY SCIENCE. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Vienna, AUSTRIA: OXFORD UNIV PRESS.
2011	Bateman, E., Bowen, J., Mayo, B., Plews, E., Darby, J., Stringer, A., . . . Keefe, D. (2011). Further characterisation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-induced diarrhoea. Poster session presented at the meeting of Abstracts of the 2011 International MASCC/ISOO Symposium, as published in Supportive Care in Cancer. Athens: Springer-Verlag. DOI
2009	Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Al-Dasooqi, N., & Keefe, D. M. K. (2009). Chemotherapy-induced diarrhoea is associated with a modified microbiome in cancer patients. Poster session presented at the meeting of Abstracts of the Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009, as published in Journal of Gastroenterology and Hepatology. Sydney, N.S.W.: Wiley-Blackwell. DOI
2000	Olver, I., Vadas, M., Lopez, A., Keefe, D., Taylor, A., Brown, M., & To, L. (2000). A phase 1 study of the GM-CSF antagonist E21R. Poster session presented at the meeting of Proceedings of ASCO - Volume 19 2000. USA: American Society of Clinical Oncology. DOI
2000	Gibson, R., Keefe, D., Clarke, J., Regester, G., Edwards, B., Thompson, F., . . . Cummins, A. (2000). Interleukin-11 (IL-11) reduces, but not completely ameliorates, intestinal mucositis following chemotherapy in the rat with breast cancer. Poster session presented at the meeting of Abstracts for Australian Gastroenterology Week 2000. Victoria, Australia: Blackwell Science Asia.

Theses

Year	Citation
2013	Al-Azri, A. S. (2013). The role of matrix metalloproteinases and their inhibitors in irinotecan-induced oral mucositis: an animal model. (PhD Thesis, The University of Adelaide).
2008	Logan, R. M. (2008). Alimentary tract mucositis: NF-kB and pro-inflammatory cytokines in the tissues and serum following chemotherapy. (PhD Thesis).

Date	Project/ No.	Investigators	Funding Body	Amount
2014	Role of Inflammatory Signalling on Burden of Illness in Mucositis.	Keefe D, Gibson R, Bowen J & Coller J	TRIAD	$12,000
2014	Prevention of dacomitinib induced diarrhoea by targeting chloride secretion.	Bowen J & Keefe D.	Pfizer	$80,000
2014	South Australian Health and Medical Research Institute – SAHMRI. Innovative Cancer Imaging and Therapeutics Facility.	C Mulligan, T Hughes, A Zannettino, S Gronthos, D White, D Keefe, T Mondo, D Roder, W Tilley, T Price and P MacKenzie	ACRF	$1.8M
2014	Cancer Data and Aboriginal Disparities – CANDAD. Development and testing of an integrated cancer monitoring and surveillance system for Aboriginal People in South Australia.	A Brown, D, Rodda, M Cargo, D Keefe, M Eckert, G Farshid	NHMRC	$1,034,270
2013	Studies on the effect of Enteragam on gastrointestinal mucositis.	D Keefe & E Bateman.	Entera Health	$100,000
2013	Protecting tissues from chemotherapy.	Callen D, Keefe D, Neilsen P, Smid S	NHMRC	$565,847
2012	Study into effect of Elsiglutide on gastrointestinal mucositis	Keefe, Bowen, Stringer and Bateman	Helsinn Healthcare	$130,000
2012	Identification Of Biomarkers Of Response And Toxicity To Chemoradiotherapy For Oesophageal Tumours	D Watson, D Keefe, D Hussey and J Bowen	NHMRC	$481,175
2012	A Nanostructured Drug Delivery Approach for Improved Colorectal Cancer Therapy.	C Prestidge, B Boyd & D Keefe	NHMRC	$541,010
2012	Cyclotherapy: a promising new approach to prevent the side effects of chemotherapy.	P M Neilsen & D M K Keefe	RAH Research Committee	$35,000
2010	Improving colorectal cancer therapy using a novel nanotechnology-based delivery system.	C Prestidge, B Boyd, MP Brown, D Keefe, A Davey	Cancer Council SA	$110,000
2010	Oral Mucositis Risk and Multicyle Chemotherapy: do multiple cycles multiply risk	L Elting, S Sonis and D Keefe	NIDCR	$150,000
2010	CCRE in Oral Health, University of Adelaide	M Bartold, J Spencer, G Townsend, K Roberts-Thompson & D Keefe	NHMRC	$2.5m
2009	Studies of Nutritional Supplements as prevention/treatment for gastrointestinal toxicity of chemotherapy		Nestec	$250,000
2008	Investigation of probiotic VSL #3 in DA rat model of mucosal injury.		VSL Pharma	$100,000
2009	Faecal microflora and circulating pro-inflammatory cytokines: key elements to chemotherapy- induced diarrhoea.	R Gibson, J Bowen, A Stringer, R Logan and D Keefe.	Cancer Australia	$75, 000
2008	Characterisation of Tyrosine Kinase inhibitor-induced gastrointestinal toxicity	D Keefe & F Boyle	GSK	$620, 000
2008	Distiller image analysis software and server	Tilley, Owens, Norman, Findlay, Keefe	NHMRC equipment grant	$52,000
2007	Automated image analysis system for the high throughput immuno-histochemical analysis of clinical and experimental samples.	Tilley, Owens, Norman, Findlay, Keefe & al	NHMRC equipment grant	$100,695.83
2007	Triad Mucositis Burden of Illness Study: Chronic mucosal injury study	Elting, Keefe & Sonis	Amgen Inc.	USD $900,000
2006	Triad Mucositis Burden of Illness Study: Acute mucosal injury cohort expansion	Elting, Keefe & Sonis	Amgen Inc.	USD $609,000
2006	Chemotherapy-induced diarrhoea: Characterisation of mechanism	D Keefe	The Cancer Council South Australia	$70,500
2006	Oral mucositis: clinical presentation, histological features and pro-inflammatory cytokine expression	R Logan, R Gibson, D Keefe & S Sonis	Australian Dental Research Foundation Inc. (ADRF)	$3000
2005	Assessment of an oral supplement in adult cancer patients with mucositis.	R Butler, P Bardy, T Price, J Davidson, D Keefe & J Webster	Biotechnology Innovation Fund (BIF) Grant	$490,000
2005	Triad Mucositis Burden of Illness Study	Elting, Keefe & Sonis	Amgen Inc.	USD $3,600,000
2005	Triad Mucositis Burden of Illness Study: project scoping study	Elting, Keefe & Sonis	Amgen Inc.	US$ 100,000
2005	Investigation of Probiotic effect on mucositis in the DA rat	D Keefe: Joint venture with Professor Claudio de Simone	VSL	$30,000
2004	Studies to investigate CG53135 for mucositis treatment in the DA rat mammary adenocarcinoma (DAMA) model	D Keefe	Curagen	USD$300, 000
2004	Oral Mucositis in humans	D Keefe	RAH Research Fund	$15,000
2003	Studies of KGF/CPT-11 in the DAMA mucositis model	D Keefe	RAHCC Internal funding	$60,000
2001	Keratinocyte growth factor research in mucositis	D Keefe	mgen Inc.	$50,000
2001	Further studies in mucositis in rats and humans undergoing cytotoxic chemotherapy f or cancer	D Keefe	Anti-cancer Foundation	$54,425
2000	Development of the DAMA model	D Keefe	RAHCC Internal Funding	$60,000
1999	Mucositis in the rat with breast cancer.	D Keefe	The Queen Elizabeth Hospital (TQEH) Research Foundation	$10,000
1999	Investigation and prevention of intestinal mucositis after chemotherapy in the rat with breast cancer	D Keefe	Anti Cancer Foundation	$52,000
1997	Mucositis research	D Keefe & A Cummins	B3 funding University of Adelaide	$5,000
1997	Mucositis Research	D Keefe & A Cummins	TQEH Research Foundation	$5,400
1995	The effect of cancer and chemotherapy on nutrition, and on inducing malabsorption by an immunological mediated enteropathy	D Keefe & A Cummins.	Anti-Cancer Foundation	$52,000

Teaching and Training Innovations and Materials Developed

Date	Course Details
2011-2017	Chair, Board of Examiners Years 4 and 5, MBBS Curriculum, University of Adelaide
2006	Initiated and chaired the inaugural meeting of the Chairs of Australian Medical School Curriculum Committees
2005	Developed and conducted the inaugural "Exam Setting Workshop" for the Year 5 final barrier exam for the new medical school curriculum.
2004-2005	Inaugural Co-ordinating Examiner for the Year 5 final barrier exam
2003-2005	Chair of Common Program subcommittee of the MBBS Curriculum Committee. Developed common program for new medical school curriculum

Curriculum Development

Date	Course Details
2004-2005	Member Assessment Committee, MBBS Curriculum
2004-2005	Member of Year 6 Committee
2003-2005	Member of Year 4/5 Committee
2002-2005	Member MBBS Curriculum Committee during development of new curriculum
1999	Member of Oncology Concept Mapping Group for development of Curriculum 2000

Curriculum Review

Date	Course Details
2006	Submission to the University of Adelaide review of the MBBS program on behalf of the curriculum committee
2006	Member of working group developing submission to the Australian Medical Council regarding accreditation of the University of Adelaide MBBS program. Accreditation achieved until 2011.
2005	Royal Adelaide Hospital Physicians’ Committee Curriculum Workshop. Developed and facilitated a review of medical student selection and assessment, as well as course structure, and generated a report for the University of Adelaide

Post Graduate Medical Training

Date	Course Details
2006-2014	RACP State representative for assessment of overseas training in Medical Oncology
2006/2011	Re-accredited supervisor for Medical Oncology Trainees of the Royal Australasian College of Physicians
1996-2007	Long-case FRACP trial examiner, Basic Physician Trainees, RAH
1999-2006	Intern Term Supervisor, Medical Oncology

Communication Skills Training

Date	Course Title
2006	NBCC Train the Trainers workshop Training future facilitators for communications workshops in cancer
2006	Medical Oncology Group of Australia, Trainee Communications Workshop Training Medical Oncology and Palliative Care Advanced Trainees in communication skills, and mentoring newly trained facilitators
2005	American Society for Clinical Oncology/Clinical Oncological Society of Australia (ASCO/COSA) communication skills workshop: Facilitator

Date

Course Title

2006

NBCC Train the Trainers workshop

Training future facilitators for communications workshops in cancer

2006

Medical Oncology Group of Australia, Trainee Communications Workshop Training Medical Oncology and Palliative Care Advanced Trainees in communication skills, and mentoring newly trained facilitators

2005

American Society for Clinical Oncology/Clinical Oncological Society of Australia (ASCO/COSA) communication skills workshop: Facilitator

Assessment

Date	Course Title
2008-2017	Chair, MBBS, Year 4/5 Board of Examiners
2007	Member of Academic Progress Review Committee Faculty of Health Sciences
2002-2006	OSCE Examiner for Medical School
2000-2010	Local Examiner for Royal Australasian College of Physicians

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2014 - 2018	Co-Supervisor	Intestinal Microvascular Changes and Matrix Metalloproteinases in Radiotherapy-Induced Gastrointestinal Toxicity	Doctor of Philosophy	Doctorate	Full Time	Romany Laura Stansborough
2011 - 2012	Co-Supervisor	The Safe Administration of Rapid Rituximab Infusion: An Evidence-Based Approach	Doctor of Philosophy	Doctorate	Full Time	Miss Siew Ping Lang
2011 - 2016	Principal Supervisor	In vitro and in vivo Models to assess the mechanism of Lapatinib - Induced Diarrhoea	Doctor of Philosophy	Doctorate	Full Time	Mrs Wan Nor I'zzah Wan Mohamad Zain
2009 - 2013	Co-Supervisor	The Role of Matrix Metalloproteinases and their Inhibitors in Irinotecan-Induced Oral Mucositis: An Animal Model	Doctor of Clinical Dentistry	Doctorate	Full Time	APrf Abdul Rahman Al 'Azri
2009 - 2014	Co-Supervisor	Optimising follow-up for women after primary treatment for early breast cancer	Doctor of Philosophy	Doctorate	Part Time	Dr Taryn Bessen
2009 - 2013	Co-Supervisor	Assessment of oral mucositis, oral health outcomes, and implementation of a standardized oral health care protocol for a pediatric inpatient population receiving cancer treatment.	Doctor of Clinical Dentistry	Doctorate	Full Time	Dr Akram Fareed Qutob
2008 - 2008	Other	Exploring the Collective Utility of Population-Based & Clinical Cancer Registries in Assessing Epidemiological, Treatment & Outcome Characteristics of Cancer in South Australia	Doctor of Medicine	Doctorate	Full Time	Dr Colin Glen Luke
2008 - 2012	Co-Supervisor	Chemotherapy-Induced Mucositis: The Role of Matrix Metalloproteinases and the Extracellular Matrix	Doctor of Philosophy	Doctorate	Full Time	Miss Noor Al-Dasooqi
2006 - 2009	Principal Supervisor	Chemotherapy-Induced Mucositis: The Role of Gastrointestinal Microflora and Mucins in the Luminal Environment	Doctor of Philosophy	Doctorate	Full Time	Dr Andrea Marie Stringer
2004 - 2008	Principal Supervisor	Alimentary Tract Mucositis: NF-KB and Pro-Inflammatory Cytokines in the Tissues and Serum Following Chemotherapy	Doctor of Philosophy	Doctorate	Part Time	Prof Richard Logan
2002 - 2004	Principal Supervisor	Chemotherapy-induced mucositis: Mechanisms of damage, time course of events and possible preventative strategies.	Doctor of Philosophy	Doctorate	Full Time	Prof Rachel Gibson
2002 - 2006	Co-Supervisor	Chemotherapy-Induced Intestinal Mucositis: The Role of Apoptosis Regulators	Doctor of Philosophy	Doctorate	Full Time	Prof Joanne Bowen

Board Memberships

Date Role Board name Institution name Country

2014 - ongoing Board Member Breast Cancer Network Australia - Australia

Date	Role	Board name	Institution name	Country
2014 - ongoing	Board Member	Breast Cancer Network Australia	-	Australia

Committee Memberships

Date	Role	Committee	Institution	Country
2014 - ongoing	Member	Inaugural Palliative Oncology Meeting	ASCO	United States
2014 - ongoing	Member	Annual Scientific Meeting	ESMO	Spain
2014 - ongoing	Member	Annual Scientific Meeting	MASCC	United States
2013 - ongoing	Member	Annual Scientific Meeting	MASCC	Germany
2013 - ongoing	Member	SA Comprehensive Cancer Consortium Steering Committee	SAHMRI	Australia
2013 - 2014	President	The Multinational Association for Supportive Care in Cancer	-	-
2012 - ongoing	Member	Annual Scientific Meeting	ESMO	Austria
2012 - ongoing	Member	Clinical Research and Drug and Device Development Pillar Committee	SAHMRI	Australia
2012 - ongoing	Member	Beat Cancer Project Research Leadership Group	SAHMRI	Australia
2011 - ongoing	Member	Annual Scientific Meeting	MASCC	Greece
2010 - ongoing	Member	Annual Scientific Meeting	European Society for Medical Oncology	Italy
2010 - ongoing	Member	Annual Scientific Meeting	Multinational Association of Supportive Care in Cancer	Canada
2010 - 2012	President	The Multinational Association for Supportive Care in Cancer	-	-
2010 - ongoing	Member	Scientific Advisory Group	SA Cancer Research Collaborative	Australia
2009 - 2013	Member	South Australian Clinical Senate	-	Australia
2009 - 2011	Member	Cancer Research Advisory Committee	The Cancer Council South Australia	Australia
2009 - ongoing	Member	Annual Scientific Meeting	Multinational Association of Supportive Care in Cancer	Italy
2008 - 2010	Vice-President	The Multinational Association of Supportive Care in Cancer)	-	-
2007 - 2010	Chair	Optimising Cancer Care Subcommittee	Cancer Clinical Network	-
2006 - 2010	Chair	Governance Subcommittee	MASCC	-
2006 - 2008	Member	Communication Steering Committee	National Breast Cancer Centre	Australia
2006 - 2008	Member	Cancer Council Helpline Advisory Panel	Cancer Council South Australia	Australia
2006 - ongoing	Member	Annual Scientific Meeting	Multinational Association of Supportive Care in Cancer/ International Society of Ocular Oncology	Canada
2005 - ongoing	Member	Annual Scientific Meeting	The Multinational Association of Supportive Care in Cancer/ International Society of Ocular Oncology	Switzerland
2005 - 2006	Member	Member Workforce Subcommittee	Statewide Cancer Control Plan	Australia
2004 - 2008	Member	Board of Directors	MASCC	Australia
2004 - 2008	Chair	Mucositis Study Group	MASCC	Australia
2004 - ongoing	Member	The Multinational Association of Supportive Care in Cancer/ International Society of Ocular Oncology	The Multinational Association of Supportive Care in Cancer/ International Society of Ocular Oncology	United States
2003 - 2011	Member	Board of Directors	The Cancer Council South Australia	Australia
2003 - 2006	Member	National Grants Steering Committee	The Cancer Council Australia	Australia
2003 - 2006	Member	Peter Nelson Leukemia Research Fellowship Committee	-	-
2003 - 2006	Chair	Cancer Research Advisory Committee	The Cancer Council South Australia	Australia
2002 - 2006	Member	Education Subcommittee	Medical Oncology Group of Australia	Australia
1999 - 2001	Member	Cancer Research Advisory Committee	The Cancer Council South Australia	Australia

Email: dorothy.keefe@adelaide.edu.au